Advantus Capital Management Inc lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,555 shares of the pharmaceutical company’s stock after purchasing an additional 369 shares during the period. Advantus Capital Management Inc owned 10,104.78% of Vertex Pharmaceuticals worth $3,885,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in VRTX. Dimensional Fund Advisors LP lifted its stake in shares of Vertex Pharmaceuticals by 2.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 272,933 shares of the pharmaceutical company’s stock valued at $29,842,000 after purchasing an additional 5,496 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 1st quarter valued at $4,387,000. Fox Run Management L.L.C. acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $619,000. Atria Investments LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $444,000. Finally, Bank of Montreal Can lifted its stake in shares of Vertex Pharmaceuticals by 31.1% in the 2nd quarter. Bank of Montreal Can now owns 208,167 shares of the pharmaceutical company’s stock valued at $26,825,000 after purchasing an additional 49,427 shares during the last quarter. 93.06% of the stock is owned by institutional investors and hedge funds.
Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) traded down $1.51 during trading hours on Friday, reaching $146.66. 75,485 shares of the company’s stock were exchanged, compared to its average volume of 1,825,265. The firm has a market capitalization of $37,277.87, a price-to-earnings ratio of 245.67, a PEG ratio of 3.74 and a beta of 1.63. Vertex Pharmaceuticals Incorporated has a 52-week low of $71.46 and a 52-week high of $167.85. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.14 and a current ratio of 3.28.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The company had revenue of $578.20 million for the quarter, compared to analyst estimates of $522.07 million. During the same period in the prior year, the business earned $0.16 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 39.7% on a year-over-year basis. analysts expect that Vertex Pharmaceuticals Incorporated will post 0.72 earnings per share for the current fiscal year.
Several research analysts recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $195.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. Cowen and Company reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 1st. BidaskClub downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 19th. BMO Capital Markets reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, September 27th. Finally, Maxim Group reiterated a “buy” rating and issued a $195.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-three have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $173.15.
COPYRIGHT VIOLATION WARNING: “Advantus Capital Management Inc Has $3.89 Million Position in Vertex Pharmaceuticals Incorporated (VRTX)” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://sportsperspectives.com/2017/11/10/advantus-capital-management-inc-has-3-89-million-position-in-vertex-pharmaceuticals-incorporated-vrtx.html.
In other news, EVP Stuart A. Arbuckle sold 6,290 shares of the company’s stock in a transaction that occurred on Friday, October 27th. The shares were sold at an average price of $143.97, for a total transaction of $905,571.30. Following the transaction, the executive vice president now directly owns 116,952 shares in the company, valued at $16,837,579.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Sangeeta N. Bhatia sold 7,073 shares of the company’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $143.05, for a total transaction of $1,011,792.65. Following the transaction, the director now owns 11,026 shares in the company, valued at $1,577,269.30. The disclosure for this sale can be found here. Insiders have sold 220,094 shares of company stock worth $32,074,719 over the last quarter. 1.80% of the stock is owned by company insiders.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.